FDA product approval
approved product. Wegovy; other approved semaglutide products have different indications.
GLP-1 and incretin · compound · checked 2026-10-09
Semaglutide
Semaglutide hits the GLP-1 receptor. Wegovy, Ozempic, and Rybelsus are approved products with different uses and forms. Compounded or research-market semaglutide is not those products. The Wegovy label says the half-life is about one week. That number describes clearance. It does not write a dosing calendar. Read the carton.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
- FDA product
- approved product
- Compounding
- not established
- Research
- product specific
- Sport
- unknown
What is Semaglutide?
Other names include Wegovy, Ozempic, Rybelsus, S-5, and several milligram research labels. Pills do not share one approval with injections. Research listings sit in a third bucket. DailyMed is the cited label home for the approved product used here.
GLP-1 receptor agonist.
Regulatory status, dated 2026-10-09
Compounding
not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.
Research
product specific. People meeting the labeled obesity/overweight and related indication criteria; evidence is product and indication specific.
Sport
unknown. Not individually verified; consult your sport authority.
What the cited papers actually measured
STEP 1 (PMID 33567185) is the widely cited obesity trial for semaglutide 2.4 mg weekly versus placebo, on top of lifestyle change, in the studied group. The Wegovy label lists stomach reactions. It lists pancreatitis warnings. It lists gallbladder disease. It also lists the rodent thyroid C-cell boxed warning with MTC/MEN2 do-not-use rules. Insulin or sulfonylurea combinations raise low-blood-sugar risk on the label. Research-market 3 mg, 5 mg, or 6 mg vials are not the trial pen.
We mark the cited papers as A. That is our label for how strong those papers are. It does not say the compound works.
How long it lasts, how you store it, listed sizes
168 hours. Approximately one week in the Wegovy label; a pharmacokinetic observation, not a schedule.
The vendor file lists 3 mg, 5 mg, and 6 mg research sizes. Approved-device storage is printed on that carton. This page does not reprint the carton.
U-100 math for listed Semaglutide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 3 mg | 30 | 15 | 10 |
| 5 mg | 50 | 25 | 16.7 |
| 6 mg | 60 | 30 | 20 |
Risks and mix-ups already on the record
- Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.
- Personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity: see the full product label.
- Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.
Sources
- Approved product label · checked 2026-10-09
- STEP 1 (PubMed 33567185) · checked 2026-10-09
- FDA concerns about unapproved GLP-1 drugs · checked 2026-10-09
Questions people ask
Does this page pick a Wegovy amount?
Labeled amounts live on the product label and with a licensed clinician. The calculator only converts numbers you type.
Why list research vial sizes at all?
People already hold those vials and ask how the U-100 math works. The chart lists a size so the algebra is visible.
Related cards
A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.